Last edition
News about " GLP-1"
Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss
Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.
GLP-1 | 04/02/2026 | By News Bureau | 241
Biocon Raises INR 4,150 Crore via QIP
Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.
GLP-1 | 15/01/2026 | By News Bureau | 113
US FDA Approves Wegovy by Novo Nordisk as first Oral GLP-1 for Weight Loss
Wegovy’s approval is supported by phase III OASIS 4 trial data showing a mean weight loss of 16.6 percent, with the oral GLP-1 indicated for long-term weight management and reduction of major adverse cardiovascular events, and Novo Nordisk planning a US launch in early January 2026.
GLP-1 | 23/12/2025 | By News Bureau | 240
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
GLP-1 | 11/10/2025 | By Dineshwori | 530
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy